Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the United States Patent Office has issued a notice of allowance for a patent covering the composition, manufacture and use of the secretion stem cell technology platform, known as Sygenus, to treat acne. We recently informed the market of the new name for the secretions platform in our Q2 2017 Update.
Regeneus Ltd (ASX:RGS) provides the Company's latest newsletter for the quarter ended 30 June 2017.
Cellmid Limited (ASX:CDY) is pleased to advise that the highest ranked paper Nature has published the results of a significant study showing for the first time that midkine, around which the Company holds extensive intellectual property rights, is a crucial agent in the promotion of melanoma metastasis.
Queensland Bauxite Ltd (ASX:QBL) is excited to announce that Medical Cannabis Limited has confirmed successful germination and growth rates of its pioneering winter Cannabis crop.
Oventus Medical Ltd (ASX:OVN) announced a share purchase plan to the market on 22 June 2017. The record date to be registered as a shareholder for participation in the SPP is Wednesday, 21 June 2017.
Oventus Medical Limited (ASX:OVN) announces that it has completed a first tranche placement of approximately 18 million shares to institutional and sophisticated investors at an issue price of $0.36 per share to raise approximately $6.5 million.
Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation for the Gold Coast Investment Showcase (June 21st & 22nd 2017).
